CAGR of 15%, Solid Tumor Therapeutics Market is expected to grow (2019-2023) Consumer research, Analytical Research Report, Business Forecast by types, by applications-The Revert News
This report separates the ability of Solid Tumor Therapeutics Market in the present and furthermore the future prospects from various edges in detail. The fundamental goal of this is to dissect the worldwide and key locales Market potential and preferred standpoint, opportunity and test, limitations and dangers.
Global “Solid Tumor Therapeutics Market 2019-2023” has been providing up and changing the worldwide economy as far as growth rate, revenue, deal, market proposition, and scope. The Global Solid Tumor Therapeutics market Consumption market report is an extensive analysis of this corporate field, which has been established to be one of the most profitable business verticals in futures. The Reportspecifies the complete estimate of Global Solid Tumor Therapeutics market business terms, in addition to presenting a brief segmentation of the industry, the expansion opportunities, as well as Key region.
Top-Listed Playersin Solid Tumor Therapeutics Market Research Report 2019-2023
- Abbott LaboratoriesInc.
- AstraZeneca PLC
- Baxter InternationalInc.
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F.F. Hoffmann-La Roche AG
- GlaxoSmithKline PLC
Get a sample copy of the report at @https://www.360researchreports.com/enquiry/request-sample/13103211
Overview of Solid Tumor Therapeutics Market:
The global solid tumor therapeutics market is expected to register a CAGR of 15% during the forecast period of 20192023. Solid tumor therapeutics are pharmaceuticals that specifically treat various cancers, such as breast cancer, lung cancer, colorectal cancer, prostate cancer, cervical cancer, and others. Solid tumors are an abnormal mass of tissue that usually does not contain cysts or liquid areas.
Increasing Incidence of Cancer
Cancer has a major impact on societies across the world. The most common cancers in 2016 were breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, bladder cancer, melanoma of the skin, non-Hodgkin lymphoma, thyroid cancer, kidney and renal pelvis cancer, leukemia, endometrial cancer, and pancreatic cancer. In 2014, an estimated 15,780 children and adolescents of ages zero to 19 were diagnosed with cancer, and 1,960 died of the disease. In 2012, 14.1 million new cases were reported worldwide. More than four out of 10 new cases of cancer were lung, female breast, bowel or prostate cancer, worldwide. So, this increasing incidence of cancer is driving the solid tumor therapeutics market.
The other factors, such as the increase in demand for POC testing, new product approvals in ovarian, pancreatic and prostate cancers, and the increase in molecular testing are driving the solid tumor therapeutics market.
Price Erosion Due to Generic Competition
The pharmaceutical company, Novartis, has seen a decline in their income due to the competition for their generic drug, Gleevec, in the United States. The generic drug became available in February 2016. The company’s net income fell from USD 2.31 billion to USD 2.01 billion in 2015.
The United States patent for the basic compound for Gleevec expired in July 2015, resulting in one of Sun Pharmaceutical Industries’ subsidiaries being allowed to sell a generic version of the drug in America from February 2016. Gleevec has already been launched in the United States, while the European launch was in December 2016. The generic copy could harm sales of Novartis’s best-selling drug, which accounts for approximately 24% of its oncology portfolio, and 15% of its pharmaceutical offering. The patent for Pemetrexed expired in Japan and major European countries in December 2015, while the United States patent expired in January 2017. Meanwhile, generics from competitors gaining approvals in Europe and Japan are expected to hamper the drug’s future sales. Ortho Biotech Oncology Research and Development, a member of the Johnson and Johnson family of companies, developed the drug, which received the US FDA approval in April 2011. It is protected by two patent licenses and is marketed by another Johnson and Johnson company, Janssen Biotech. A lawsuit was filed against Mylan regarding the filing of an abbreviated new drug application (ANDA) with the US FDA for producing a generic version of Zytiga. These generic medicines are hindering the growth of the solid tumor therapeutics market. The other factors, such as expensive procedures and regulatory complications are also hindering the growth of the market.
United States Leads the Market in North America
The United States solid tumor therapeutics market held the largest market share in 2017 in the North American region due to the presence of high-quality healthcare system and modern medical technology in the country. Additionally, the growing awareness about cancer among the public is likely to contribute towards the growth of the solid tumor therapeutics market.
Share your query before purchasing this report @https://www.360researchreports.com/enquiry/pre-order-enquiry/13103211
Key Highlights from Solid Tumor Therapeutics Market Report 2019.
Revenue and Sales Estimation — Historical Revenue and sales volume is presented and further data is triangulated with top-down and bottom-up approaches to forecast complete market size and to estimate forecast numbers for key regions covered in the report along with classified and well recognized Types and end-use industry. Additionally, macroeconomic factor and regulatory policies are as curtained in Solid Tumor Therapeutics industry evolution and predictive analysis.
Manufacturing Analysis —the report is currently analyzed concerning various product type and application. The Solid Tumor Therapeutics Market provides a chapter highlighting manufacturing process analysis validated via primary information collected through Industry and Key officials of profiled companies.
Competition — Leading players have been analyzed depending on their company profile, product portfolio, capacity, product/service price, sales, and cost/profit.
Demand and Supply and Effectiveness — Solid Tumor Therapeutics Market report additionally provides distribution, Production, Consumption for the complete industry.
Solid Tumor Therapeutics MarketTop Regions(regional analysis covers):-
- North America (the USA, Canada, andMexico)
- Europe (Germany, France, UK, Russia, andItaly)
- Asia-Pacific (China, Japan, Korea, India, andSoutheast Asia)
- South America, Middle East, andAfrica
Reasons to Purchase the Report
- Follow the current and future global solid tumor therapeutics market in the developed and emerging markets.
- Examining the various perspectives of the market with the help of Porter’s Five Forces Analysis.
- Identify the segment that is expected to dominate the market.
- Identify the regions that are expected to witness the fastest growth during the forecast period.
- Identify the latest developments, market shares, and strategies employed by the major market players.
- 3-month analyst support along with the Market Estimate sheet (in Excel).
Buy this report (Price 4250 USD for a single-user license) @https://www.360researchreports.com/purchase/13103211
Solid Tumor Therapeutics Market 2019 Report Brief:-
- The report covers forecast and analysis for the Solid Tumor Therapeutics market on a global and regional level
- The report includes the drivers and the restraints that affect the growth of the market
- Detailed information about the market opportunities are discussed
- The key target audience for the market has been determined in the report
- The revenue generated by the prominent industry players has been analyzed in the report
- The market numbers have been calculated using top-down and the bottom-up approaches
- The market is segmented on the basis of product, technology, ownership, and end-user industry which in turn is bifurcated on the regional level as well
- All the segments have been evaluated based on the present and the future trends
- The report deals with the in-depth quantitative and qualitative analyses of the Solid Tumor Therapeutics market
- The report includes detailed company profiles of the prominent market players
Look into Table of Content of Solid Tumor Therapeutics Market 2019 Research Report at
About 360 Research Reports:
360 Research Reports is a credible source for gaining the market reports that will provide you with the lead your business needs. At 360 Research Reports, our objective is providing a platform for many top-notch market research firms worldwide to publish their research reports, as well as helping the decision makers in finding most suitable market research solutions under one roof. Our aim is to provide the best solution that matches the exact customer requirements. This drives us to provide you with custom or syndicated research reports.
360 Research Reports
Mr. Ajay More
USA: +1 424 253 0807
UK: +44 203 239 8187
Press Release Distributed by The Express Wire
To view the original version on The Express Wire visit CAGR of 15%, Solid Tumor Therapeutics Market is expected to grow (2019-2023) Consumer research, Analytical Research Report, Business Forecast by types, by applications